ArticlemAbs2026
Application of protein language models for antibody developability prediction.
Article in mAbs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein language models (PLMs) provide a powerful framework for learning sequence - property relationships in antibodies. However, their performance and reliability in real-world industrial antibody discovery pipelines remain underexplored. Here, we systematically evaluate several state-of-the-art PLMs using internal datasets comprising antibody sequences and developability assay measurements from 33 historical therapeutic programs. The assays span three critical developability dimensions: polyspecificity reagent (PSR), hydrophobic interaction chromatography (HIC), and affinity-capture self-interaction nanoparticle spectroscopy (AC-SINS). Across all assays, domain-adaptive fine-tuning of PLMs on internal antibody sequence data consistently improves predictive performance relative to pretrained representations alone. In addition, we assess sequence likelihoods derived from pretrained PLMs as unsupervised indicators of developability risk and analyze their strengths and limitations across assay types. Together, these results demonstrate that PLMs can provide robust and complementary signals for antibody developability assessment, supporting their practical use in early-stage candidate optimization and selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.